On March 5, Novo Nordisk released the top-line results from this pivotal kidney outcomes trial: Use of semaglutide in patients with diabetic kidney disease reduced the primary outcomea composite of kidney failure, 50% decline in estimated glomerular filtration rate (eGFR), and cardiovascular (CV) or kidney deathby an impressive 24% (Figure 1)
Get Readers Digest s Read Up newsletter for more etiquette tips, humor, cleaning, travel, tech and fun facts all week long
Portions become smaller, and you finally feel full after eating
And energy levels usually stabilize
Ipamorelin is more selective (no cortisol/prolactin release)
If you increase your insulin dose significantly after the steroid injection, you end up risking hypoglycaemia